OAM
SLRN

Oxford Asset Management’s ACELYRIN SLRN Stock Holding History

Oxford Asset Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,276
Closed -$54.1K – 433
2024
Q2 		$54.1K Buy
+12,276
New +$57.5K 0.05% 262

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Oxford Asset Management's SLRN Position: Q3 2024 in Review

Oxford Asset Management sold out of ACELYRIN (SLRN) in Q3 2024, closing a stake of 12,276 shares — an estimated $54.1K sold.

Oxford Asset Management first reported a position in SLRN in Q2 2024 and held it in 1 quarter. The position peaked at $54.1K in Q2 2024. 122 funds tracked by Wall St. Rank hold SLRN as of Q3 2024.

  • Oxford Asset Management reported no remaining ACELYRIN position as of Q3 2024 after selling out during the quarter.
  • Oxford Asset Management sold 12,276 ACELYRIN shares in Q3 2024, an estimated $54.1K.
  • Oxford Asset Management first reported a position in ACELYRIN in Q2 2024 and held it in 1 quarter.
  • Oxford Asset Management's ACELYRIN position peaked at $54.1K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2024.

Based on Oxford Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.